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Staging for Prostate Cancer
Time to Incorporate Pretreatment Prostate-specific Antigen and Gleason Score?
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BACKGROUND. The American Joint Committee on Cancer (AJCC) staging system
for prostate cancer is based primarily based on clinical tumor (T) classification.
In this article, the authors summarize arguments for incorporating additional
pretreatment parameters and creating a new staging system for prostate cancer.
METHODS. Men with localized prostate cancer who received treatment with exter-
nal beam radiation alone were analyzed using the 1997 AJCC staging system
compared with a system that included pretreatment prostate-specific antigen
(pPSA) level and Gleason score (GS). Multivariate analyses using a Cox propor-
tional-hazards model were carried out to evaluate T classification, GS, and pPSA
as predictors of overall survival (OS), disease-specific survival (DSS), and freedom
from PSA failure (FFPF).
RESULTS. Based on pretreatment characteristics in a series of contemporary
patients, only 0.6% of patients were classified with AJCC stage I disease, 16.0%
were classified with AJCC stage III disease, and 83.4% were classified with AJCC
stage II disease. Multivariate analyses indicated the independent statistical signif-
icance of T classification, GS, and pPSA in predicting OS, DSS, and FFPF (model
chi-square value, P < .0001 for each). Using these 3 predictors, subsets of patients
who had similar outcomes were combined to provide examples of the insensitiv-
ity of the AJCC system for predicting outcomes. Incorporating pPSA and GS
allowed the identification of differences in OS, DSS, and FFPF for subsets of patients
with AJCC stage II disease (P < .0001, P ¼ .005, and P < .0001, respectively).
CONCLUSIONS. The current AJCC staging system does not divide contemporary
patients with prostate cancer into prognostic subgroups and does not identify
patients who have comparable biochemical control and survival. The AJCC sta-
ging system for prostate cancer should be changed to incorporate pPSA, GS, and
risk stratification. Cancer 2007;109:213–20.  2006 American Cancer Society.
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I deally physicians should be able to apply the American JointCommittee on Cancer (AJCC) staging system for prostate cancer
to estimate the risk of cancer recurrence and survival. Historically,
tumor (T) classification, lymph node (N) status, and the presence of
metastases (M) have been the cornerstones of staging for solid
tumors. Unfortunately, the exclusive use of the current TNM staging
system has limited relevance to predicting outcome and directing
therapy for men with clinically localized prostate cancer. In part,
this limitation is because nearly 75% of men who currently are diag-
nosed with clinically localized prostate cancer have nonpalpable
disease, and the incidence of lymph node involvement is <4% in
men who undergo radical prostatectomy.1
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Most clinicians agree on how to identify which
patients have the lowest and highest risk of develop-
ing a disease recurrence. It is the intermediate AJCC
subset that is most heterogeneous in terms of out-
comes, including biochemical failure and survival.
Clearly, the current staging system is inadequate and
could be improved by incorporating reproducible
prognostic factors. In this article, we propose a
change in the AJCC staging system that improves its
relevance to newly diagnosed patients with prostate
cancer. In doing so, we hope to improve the ability
of physicians and patients to communicate, compare
outcomes, and select the most appropriate treat-
ment. By accomplishing this feat, we hope to foster
greater uniformity when multi-institutional compari-
sons are made.
Recent studies have shown that the serum level
of prostate-specific antigen (PSA) is associated with
the presence of occult prostate cancer, even in men
with normal levels.2 More than 10 years ago, it also
became clear that the pretreatment PSA (pPSA) level
was the most important predictor of biochemical
(PSA) recurrence after radiotherapy. For >10, years it
has been known that the Gleason score (GS) was the
most important predictor of death.3,4 Recognition of
the value of combing these 2 factors with T classifi-
cation to create prognostic risk groups followed
shortly thereafter.4–7 Over the last few years, PSA has
been confirmed as an important predictor of mortal-
ity from prostate cancer.8–12
Ideally, a large, multicenter, prospective registra-
tion trial should be used to define and validate a
new staging system. In the meantime, we believe
that there are enough data currently available to jus-
tify practical changes to the AJCC system. Herein, we
suggest some characteristics of a new staging system
based on literature published in major peer-reviewed
journals that incorporate the best evidence available
and the current practice patterns.
MATERIALS AND METHODS
Evidence Supporting the Incorporation of PSA and GS
The comparative analysis presented here was based
on data from 912 patients who received treatment
for localized prostate cancer between 1987 and 1998
at the University of California San Francisco and at
the University of Michigan.13 Patients with metastatic
disease who received radiation therapy up to a maxi-
mum dose <60 grays (Gy), who received neoadjuvant
or adjuvant hormone therapy, or who had no PSA
follow-up after external beam radiotherapy (EBRT)
and patients with missing pPSA, GS, or T classifica-
tion information were excluded from this analysis. To
evaluate biochemical failure, patients who had <2
years of follow-up from the end of EBRT who did not
have evidence of biochemical, local, or distant dis-
ease recurrence also were excluded. The early failures
or deaths that were caused by prostate cancer were
included, thus minimizing the risk of inflating early
estimates of freedom from PSA failure (FFPF). This
resulted in a cohort with complete information on
pPSA, GS, and T classification and with adequate fol-
low-up, with 95% of the patients treated prior to
1997, so that all patients could be classified by multi-
ple risk definitions to compare differences in out-
come. The distribution according to AJCC stage, T
classification, GS, and pPSA is presented in Table 1.
The median follow-up from the end of EBRT for
surviving patients was 69 months with 47% of
patients surviving for >6 years and 24% surviving >8
years. Regular PSA follow-up measurements were
obtained approximately every 3 to 6 months. Patients
were treated with either conventional (21%) or 3-
dimensional (3D) conformal radiotherapy (79%), as
determined by their physician, to maximum doses
that ranged from 60 Gy to 87.3 Gy. The median maxi-
mum dose was 70 Gy for conventional radiotherapy
and 70.4 Gy for 3D conformal radiotherapy.
The American Society of Therapeutic Radiation
Oncology consensus definition of biochemical fail-
ure, which requires 3 consecutively increasing PSA
measurements, was applied to determine FFPF.14
According to this definition, the date of failure was
modified to be the midpoint between the first of the
3 rising PSA levels and the date of the PSA obtained
prior to the 3 rising values. Failures also included
TABLE 1
Distribution of Patients (N = 912)
AJCC Stage
No. of patients (%)
GS 2–6* GS 7 GS 8–10
Stage I
T1 5 (0.6)* — —
Stage II
T1-T2 493 (54) 205 (22) 63 (7)
pPSA <10 ng/mL 248 79 14
pPSA 10 ng/mL-<20 ng/mL 136 66 23
pPSA 20 ng/mL 109 60 26
Stage III
T3 47 (5) 57 (6) 41 (5)
pPSA <20 ng/mL 27 20 13
pPSA 20 ng/mL 20 37 29
AJCC indicates American Joint Committee on Cancer staging system; GS, Gleason score; pPSA, pre-
treatment prostate-specific antigen level; T, clinical tumor classification.
* AJCC stage I includes only GS 2–4.
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patients with local or distant disease (n ¼ 59),
patients who died with prostate cancer (n ¼ 4),
patients who received any hormone intervention
prior to a PSA failure (n ¼ 33), and patients who had
a marked increase in PSA within the timing or rou-
tine follow-up (n ¼ 12). If no failure occurred, then
patients were censored at the date of the last PSA
follow-up. Death from any cause determined overall
survival (OS). Death from prostate cancer (disease-
specific survival [DSS]) was determined from a
review of death certificates and hospital charts.
Patients who had metastatic disease at the time of
death were classified as having died of prostate can-
cer, even if other causes were listed as contributing
factors. Patients who did not die were censored as of
the date of last contact. All failure endpoints (OS,
DSS, and FFPF) were measured from the end of
EBRT.
Statistical Analysis
The Kaplan-Meier product-limit method was used to
estimate the probability of biochemical failure and
survival.15 The log-rank test was used to formally
compare the distributions of time to failure for sub-
sets of the AJCC staging groups or according to the
newly proposed staging system. In an attempt to de-
velop a new staging system that expanded the AJCC
staging system beyond the current method, which is
based primarily on T classification, multivariate anal-
yses were conducted. A Cox proportional-hazards
model with a stepwise forward technique was used
to evaluate T classification, GS, and pPSA simulta-
neously as predictors of OS, DSS, and FFPF.16 These
3 potential predictors were treated categorically so
that we would be able to define subsets of these fea-
tures for patients who had a comparable risk of fail-
ure. GS and pPSA were not considered as continuous
variables, because this would be assuming a constant
proportional-hazard ratio over the range of values.
Indicator variables were used for each of these 3 fac-
tors by using traditional cut-off points (T1-T2 and
T3; GS 2–6, GS 7, and GS 8–10; and pPSA <10 ng/
mL, from 10 ng/mL to <20 ng/mL, and 20 ng/mL).
The patients who were included in this analysis were
classified initially according to the 1997 fifth edition
of the AJCC classification system, in which stage I
includes patients with T1a tumors and a GS from 2
to 4; stage II includes patients with T1a tumors and
a GS from 5 to 10 and patients with T1b, T1c, or T2
tumors; and stage III includes patients with T3
tumors).17 The likelihood ratio (LLR) test was used to
compare models to determine which factors were
significant, independent predictors of outcome. Sub-
sets were combined based on nonsignificant log-rank
tests to identify subsets of patients that had a similar
risk of death or biochemical failure.
RESULTS
Only 0.6% of patients were classified with AJCC stage
I disease, and 16% were classified with AJCC stage III
disease; thus, the majority of patients were classified
with AJCC stage II disease (83.4%). Because only 5
patients were classified with AJCC stage I disease,
this subset is not included in the statistical compari-
sons described below. FFPF, DSS, and OS differed
significantly between AJCC stage II and stage III (P
< .0001 for all 3 endpoints). The 5-year estimates of
FFPF, DSS, and OS for patients with AJCC stage II
disease were 54%, 96%, and 87%, respectively; for
patients with AJCC stage III disease, the FFPF, DSS,
and OS estimates were 18%, 83% and 71%, respec-
tively. Further discrimination within AJCC risk groups
II and III also can be observed by considering the
3 GS subsets (2–6, 7, and 8–10) within each T-classifi-
cation group. Again, significant differences in FFPF,
DSS, and OS were observed for patients with AJCC
stage II disease (P < .0001, P ¼ .0004, and P ¼ .0001,
respectively). This indicates that the AJCC stage II
group represents pooled subsets of patients with
variable outcomes. For patients with T3 disease, the
patients with AJCC stage III disease, a difference in
FFPF according to GS occurred (GS 2–6 vs 7 vs 8–10;
P ¼ .01). Death occurred at the same rate among the
T3 subsets, reflecting the fact that 82% of the
patients were diagnosed with a GS 7 and/or a pPSA
20 ng/mL.
The AJCC staging groups were also subdivided
according to pPSA (<10, from 10 ng/mL to <20 ng/
mL, and 20 ng/mL). Again, the inclusion of pPSA
demonstrated that the current staging system is
inadequate, as indicated by the significant differ-
ences in FFPF, DSS, and OS for the patients with
AJCC stage disease caused by their pPSA level
(P < .0001, P ¼ .0003, and P ¼ .0003, respectively). A
difference in biochemical failure also can be
observed between pPSA <20 ng/mL and PSA 20
ng/mL in patients with AJCC stage III disease (P
¼ .002).
Multivariate analysis indicated the strong inde-
pendent statistical significance of T classification,
GS, and pPSA in predicting FFPF (model LLR test:
P<.0001). Analyses were repeated with the outcome
variables changed to reflect later endpoints in dis-
ease progression; again, the results indicated the in-
dependent, statistically significant benefit of a T1 or
T2 tumor classification and a pPSA level <20 ng/mL
in predicting DSS and OS (model LLR test: P < .0001
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for both endpoints). Among the patients with AJCC
stage II disease, controlling for the T-classification
effect, both GS and pPSA were significant independ-
ent predictors of all 3 outcomes (model LLR tests:
FFPF, P < .0001; DSS, P ¼ .0005; OS, P < .0001).
Among the patients with AJCC stage III disease,
which is the T3 group, pPSA levels 20 ng/mL and a
GS from 8 to 10 were significant independent predic-
tors of poorer FFPF (model LLR test: P ¼ .0006).
Receiving a diagnosis of T3 disease, regardless of GS
or pPSA, indicated poor DSS or OS.
Combinations of subsets according to T classifi-
cation, GS, and pPSA for patients with AJCC stage II
and stage III disease were defined by using the
results for predictors of DSS that were identified in
the Cox multivariate model described above. There
was no difference in DSS among patients who had
T1 or T2 tumors and a GS from 2 to 6 between those
with a pPSA level of <10 ng/mL and a pPSA from 10
ng/mL to <20 ng/mL (P ¼ .60). The final combina-
tion of subsets was based on nonsignificant log-rank
tests, resulting in 3 distinct new risk groups (Table
2), hereafter referred to as the new stages. This new
staging system is predictive of OS, DSS, and FFPF
(log-rank test; P<.0001 for all 3 endpoints) and does
not indicate a strictly additive model of predictors.
By applying this new system, 28% (rather than
0.6%) of contemporary patients would have a more
favorable outcome with 5-year estimates of FFPF,
DSS, and OS for patients with newly diagnosed stage
I prostate cancer of 72%, 98%, and 89%, respectively
(data not shown). In addition, 26% of patients would
be identified as having an increased risk of failure
compared with the AJCC stages. Only 47% of patients
would be classified similarly by both staging systems,
and this would include all patients with T3 tumors
(16%). The shifts in classification are limited to all
but 1 patient with AJCC stage II disease. As is shown,
the new staging definition, as shown in Figure 1A,
1B, and 1C), identifies a greater proportion of the
patients with AJCC II disease who would be at a
reduced risk of failure and death than would be
anticipated by the current AJCC criteria. Distinct
prognostic subsets can be identified within AJCC
stage groups II and III based on GS and pPSA.
Among patients who had AJCC stage II disease with
an overall 5-year DSS probability of 96%, there was a
significant difference when the new staging system
was used for the analysis (P ¼ .005). The 5-year esti-
mates of DSS for the 3 new stages (1 through 3) were
98%, 98%, and 93% (Fig. 1C). This new staging sys-
tem also indicated a significant difference in FFPF
with 5-year estimates for the new stages of 72%,
52%, and 37% (Fig. 1A), respectively, and a significant
difference in OS, with 5-year estimates of 89%, 92%,
and 81% (Fig. 1B) for patients with AJCC stage II dis-
ease (P < .0001 for each). All of these T3 patients are
at increased risk of failure, but a subset of them with
a GS from 8 to 10 and pPSA 20 ng/mL was identi-
fied that had a poorer outcome, especially in terms
of FFPF (P ¼ .003) and DSS (P ¼ .01). Among patients
with AJCC III who had an 18% FFPF at 5 years, this
higher risk subset of the new stage III patients had a
significantly poorer outcome, with an only 10% FFPF
rate at 5 years compared with 20% for patients who
did not have both of these unfavorable features at di-
agnosis (data not shown). Similarly, with an overall
83% 5-year DSS rate, the estimate was 71% for the
higher risk subset compared with 86% for the re-
maining AJCC stage III (T3) patients. Thus, this new
staging system has identified subsets of patients
within both the stage II and stage III AJCC groups
that had similar outcomes and who are at greatest
risk of failure.
DISCUSSION
Despite the widespread recognition of serum PSA as
a marker for the presence of disease, for the extent
of disease, and as a prognostic factor for recurrence
and death, to date, the PSA level has not been incor-
porated into the current staging system. Similarly, GS
not only has been known as a predictor of pathologic
stage but may be the most important predictor of
TABLE 2
Proposed ‘‘New’’ Prostate Cancer Staging System
Classification Definition
TX Tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
New stage I T1-T2, GS 6, and PSA <10 ng/mL
New stage II T1-T2, GS 6, and PSA <10-20 ng/mL
Or T1-T2, GS 7, and PSA <20 ng/mL
Stage IIA T1-T2, GS 6, and PSA 10-<20 ng/mL
Stage IIB T1-T2, GS 7, and PSA <20 ng/mL
New stage III T1-T2, GS 6, and PSA 20 ng/mL
Or T1-T2, GS 7, and PSA 20 ng/mL
Or T1-T2 and GS 8–10
Or clinical T3 disease
Stage IIIA T1-T2, GS 6, and PSA 20 ng/mL
Or T1-T2, GS 8–10, and PSA <20 ng/mL
Stage IIIB T1-T , GS 7, and PSA 20 ng/mL
Stage IIIC Clinical T3 disease, seminal vesicle or bladder neck invasion
NX Lymph nodes cannot be assessed
N0 No regional lymph node involved
N1 Metastases, regional lymph node(s)
GS indicates Gleason score; PSA, prostate-specific antigen.
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death from prostate cancer. It, too, largely has been
ignored in the current AJCC staging system.
Because of widespread PSA screening, the pre-
dominance of nonpalpable (T1c) disease, and de-
clines in the use of transurethral resection of the
prostate, this staging system may no longer be ade-
quate for classifying contemporary patients. In parti-
cular, patients with AJCC stage I prostate cancer
(clinical stage T1a with a GS from 2 to 4) rarely are
diagnosed, so that newly diagnosed patients essen-
tially are being classified as either having or not hav-
ing clinical stage T3 disease (palpable extension
beyond the prostate). Thus, as the frequency of diag-
nosing clinical T3 tumors decreases, the majority of
currently diagnosed patients are classified as with
AJCC stage II prostate carcinoma, and these patients
do not have a uniform prognosis. For this group of
patients, other disease features, including GS, pPSA
levels, and the percentage of positive biopsies, are
strong, independent predictors of pathologic stage
and outcome. This has led to the practice of combin-
ing these and other features to identify subsets of
patients with similar outcomes.
There is general agreement about how to identify
patients at the lowest and highest risk of disease re-
currence. It is the intermediate AJCC subset that is
most heterogeneous in terms of outcomes, including
biochemical failure and survival. Clearly, the current
staging system is inadequate and could be improved
by incorporating these reproducible prognostic fac-
tors. The objective of this article was to propose a
change in the AJCC staging system that would
improve its relevance to patients who are newly diag-
nosed with prostate cancer. In doing so, we hope to
improve the ability of physicians and patients to
communicate, compare outcomes, and select the
most appropriate treatment.
A Practical Solution Based on the Standard of Care?
Currently, there is a compelling body of evidence to
support the notion that pPSA and GS should now
move beyond risk-stratification systems and also
should be incorporated into our staging system. In
response to the shortcomings of the current AJCC
staging system for prostate cancer, the medical com-
munity, in a sense, has voted with their feet. Risk
stratification has become the mantra for predicting
FIGURE 1. Among patients with American Joint Committee on Cancer
stage II (AJCC II) prostate cancer, who have an overall 5-year disease-speci-
fic survival (DSS) probability of 96%, there was a significant difference
according the analysis with the new staging system (P ¼ .005). The new
system also indicated significant differences in freedom from prostate-speci-
fic antigen failure (FFPF), with 5-year estimates for new stages I through III
of 72%, 52%, and 37%, respectively (A), and significant differences in over-
all survival (OS), with 5-year estimates of 89%, 92%, and 81% (B), respec-
tively (P < .0001 for each). The 5-year estimates of DSS for new stages I
through III were 98%, 98%, and 93%, respectively (C). EBRT indicates exter-
nal beam radiotherapy.
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prognosis and for directing therapy. Tables 3 and 4
summarize the criteria used to define patients who
are considered to be at low risk of recurrence and
death from several radiotherapy series. It can be seen
in Table 3 that there is remarkable consistency
among investigators from the United States, Austra-
lia, and Canada, with the last group formally reach-
ing a consensus.38 Although they are not quite as
uniform, definitions of intermediate-risk disease also
are very similar. Even investigators who have chosen
to use equations or nomograms, as shown in Table 4,
yield similar end results when they examined pa-
TABLE 3
Criteria for Defining Low-risk Patients from Selected Modern Radiotherapy Series
Institution(s) (Alphabetical Order) Reference(s) T Classification GS PSA Comments
Canadian multicenter study Crook et al., 200418 T1-T2a 6 <10 ng/mL Prospective Phase III trial evaluating
3-mo vs 8-mo NHT
CAPSURE Cooperberg et al., 200319 T1-T2a 6 10 ng/mL Longitudinal data from 30 academic and
community-based urology practices
Cleveland Clinic and Mercy
Medical Center Kupelian et al., 2004
20
T1-T2a 6 <10 ng/mL Used to compare EBRT with PPI 6 EBRT to RP
FCCC Lattanzi et al., 199721 T1-T2 2–7 <8 ng/mL Predictors of outcome after 3DCRT
FCCC Chism et al., 200422 T1-T2c 6 <10 ng/mL Compared single vs multiple factors
Harvard Joint Center D’Amico et al., 19985 T1c-T2a 6 10 ng/mL Used to compare EBRT to PPI and RP
Harvard Joint Center D’Amico et al., 2002, 200423,24 T1c-T2a 6 10 ng/mL PPBs >50% vs <50% correlated with outcome
Harvard, MGH Zietman et al., 200425 T1-T2 6 <10 ng/mL 10-y results comparing favorable with unfavorable
MD Anderson Selek et al., 200326 T1-T2a 6 <10 ng/mL PPBs >50% vs <50% did not correlated
independently with outcome
Mount Sinai Lee et al., 200227 T1-T2a 6 <10 ng/mL Patients treated with PPI 6 EBRT and NHT
MSKCC Potters et al., 200428 T1-T2 6 10 ng/mL Also used PPB <50% and cores to stratify
MSKCC Zelefsky et al., 1998, 200229,30 <T2c 6 10 ng/mL Studies using 3DCRT and IMRT




Kuban et al., 200332 T1b, T1c, T2a 6 10 ng/mL Long-term follow-up of >4000 patients
who received EBRT
WBRC (Australia) Williams et al., 200433 T1c-T2a 6 10 ng/mL Compares this grouping with those by Pisansky,
Shipley and Leibel
Wheeling West Virginia Merrick et al., 200234 T1c-T2a 6 10 ng/mL PPI 6 EBRT also analyzed by
PPBs <34%, 34–50%, and >50%
T indicates tumor; GS, Gleason score; PSA, prostate-specific antigen; NHT, neoadjuvant hormone therapy; CAPSURE, Cancer of the Prostate Strategic Urologic Research Endeavor; EBRT, external beam radiother-
apy; PPI, permanent prostate seed implantation; 6, with or without; RP, radical prostatectomy; FCCC, Fox Chase Cancer Center; 3DCRT, 3-dimensional conformal radiotherapy; PPBs, percent positive biopsies;
MGH, Massachusetts. General Hospital; M D Anderson: The University of Texas M. D. Anderson Cancer Center; MSKCC, Memorial Sloan-Kettering Cancer Center; IMRT, intensity-modulated radiotherapy;
WBRC, William Buckland Radiotherapy Center (Melbourne, Australia).
TABLE 4
Criteria for Defining Low-risk Patients from Selected Modern Radiotherapy Series
Institution(s) (Alphabetical Order) Reference(s) T Classification GS PSA, ng/mL Comments
MSKCC Kattan et al., 20007 T1c-T2a* 6* 10* Based on nomogram using these
parameter similar results*
RTOG Roach et al., 20004 T1-T2 6 NA RTOG risk groups
RTOG Michalski et al., 199935 T1-T2 6y or 7 15y or <5 Calculated risk of positive SV <15%*
UCSF and UM Speight et al., 199936 NA —{ —{ Calculated risk of positive lymph nodes <15{
UCSF and UM Roach et al., 200037 NA —§ —§ Calculated risk of ECE <34% vs 34–66% vs >66%
UCSF and UM Roach et al., 20038 T1-T2 6 <10 vs 10-<20, vs 20 RTOG risk groups
T indicates tumor; GS, Gleason score; PSA, prostate-specific antigen; MSKCC, Memorial Sloan-Kettering Cancer Center; RTOG, Radiation Therapy Oncology Group; NA, not available; RTOG, Radiation Therapy
Oncology Group; SV, seminal vesicles; USCF, University of California San Francisco; UM, University of Michigan; ECE, extracapsular extension.
* Used as parameters in a nomogram to predict outcome.
y Risk of positive SV ¼ (PSA) þ [(GS-6)  10].
{ Risk of positive lymph nodes ¼ ((2/3) PSA) þ [(GS 6)  10].
§ Risk of ECE ¼ [(3/2) PSA] þ [(GS 3)  10].
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tients with PSA levels <10 ng/mL, GS 6, and T1 or
T2 tumors; thus, there is relatively little controversy
about this category. With the growing use of risk
stratification in both the current literature and in the
language of clinical practice, the staging system here
proposed is consistent with practice and improves
on the current AJCC system without being overly
complicated.
In the current analysis, we did not include the
percent of positive cores despite a plethora of publi-
cations supporting the independent prognostic sig-
nificance of this variable, because we do not possess
such data.23,24,39–41 We recognize, however, that this
growing body of literature suggests that, some time
in the near future, such information may be useful
for defining subcategories within the staging system.
Until that day comes, we believe that incorporating
the major clinical features described above would be
an important step forward that is supported by a
preponderance of the available clinical evidence.
In conclusion, every major recent series that has
reported prostate cancer outcomes used a risk-classi-
fication scheme based on PSA and GS in addition to
clinical T classification. None of the recently pub-
lished series have reported outcomes using the cur-
rent AJCC staging system. Now, we believe that it is
time to incorporate the well recognized prognostic
factors discussed here into a new staging system and
that our proposed system represents a reasonable
starting point.
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